Loading stock data…
ARQT
$23.35+0.13 (+0.56%)
After Hours$23.35+0.00 (+0.00%)· Last close May 1
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arcutis Biotherapeutics, Inc. in the Healthcare sector is trading at $23.35. The stock is currently 27% below its 52-week high of $31.77, remaining 2.2% above its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why ARQT maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$23.35
Potential Upside
5%
Whystock Fair Value$24.52
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.97B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.22%
Volume
Today's trading volume
987,134
Recent News
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Moves
Assessing recent moves in Arcutis Biotherapeutics (ARQT) Arcutis Biotherapeutics (ARQT) has drawn attention after a recent share price move, with the stock closing at US$22.86 and showing mixed performance over the past week, month, and past 3 months. See our latest analysis for Arcutis Biotherapeutics. While the latest 1-day share price return of 3.75% decline and 7-day share price return of 5.50% decline point to fading short-term momentum, the 1-year total shareholder return of 55.30%...
How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 Target
Arcutis Biotherapeutics now sits at the center of a fairly tight cluster of Street price targets, with several analysts coalescing around about $35 after recent model updates. Those tweaks, which include both upward and downward revisions into the mid $30s, are being tied directly to Q4 results, refreshed guidance, and evolving views on the Zoryve rollout. As you read on, you will see how these small shifts feed into the broader analyst narrative and what to watch as new data points...
Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants
Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the 10 Overlooked Growth Stocks to Buy Now. Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the overlooked growth stocks to buy now. On March 28, Arcutis Biotherapeutics presented new Phase 2 data from its INTEGUMENT-INFANT trial at the 2026 American Academy of Dermatology Annual Meeting. The study evaluated […]